Vol. 7, Issue 1, Part A (2025)

Medication-induced psychosis is a clinically significant condition resulting from the adverse effects of various pharmacological agents on brain function. It often mimics primary psychotic disorders, complicating diagnosis and management across multiple medical disciplines. This review examines the pathophysiology, clinical presentations, diagnostic challenges, and management strategies associated with medication-induced psychosis. Neurotransmitter imbalances, medication dosages, and individual susceptibility are identified as key contributors to its development. The diagnostic process requires distinguishing medication-induced psychosis from primary psychiatric disorders through detailed patient histories and a high index of clinical suspicion. Effective management strategies focus on discontinuing the causative agent, administering antipsychotics when necessary, and implementing preventive measures, including patient education and risk mitigation. Future developments in pharmacogenomics, targeted drug design, and early detection techniques may revolutionize the prevention and treatment of medication-induced psychosis. By integrating interdisciplinary research and clinical insights, healthcare providers can improve therapeutic safety and efficacy, enhancing patient outcomes and minimizing the risks associated with psychoactive medications.